Showing results (211-220 of 237) with videos related to
Sort By:
Pageof 24
Cancer Science|July 24, 2012
Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in JapanYasuhiro Oki, Yutaka Kondo, Kazuhito Yamamoto, et al.Leukemia & Lymphoma|November 28, 2018
BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphomaYoshikazu Ito, Tomohiro Umezu, Kenichi Tadokoro, et al.International Journal of Hematology|February 24, 2012
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II studyKensuke Usuki, Arinobu Tojo, Yasuhiro Maeda, et al.Cancer Science|June 1, 2011
Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromesToshiki Uchida, Yoshiaki Ogawa, Yukio Kobayashi, et al.Leukemia Research|February 7, 2018
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first studyYuho Najima, Chikashi Yoshida, Noriyoshi Iriyama, et al.Leukemia Research|April 28, 2012
Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?Athena M Cherry, Marilyn L Slovak, Lynda J Campbell, et al.International Journal of Hematology|April 27, 2017
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 studyArinobu Tojo, Taiichi Kyo, Kazuhito Yamamoto, et al.International Journal of Hematology|July 29, 2016
Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in JapanHaruhiko Ninomiya, Naoshi Obara, Shigeru Chiba, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 25, 2012
Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional studyTetsuya Matsumoto, Hideaki Hanaki, Toshimi Kimura, et al.International Journal of Hematology|May 19, 2009
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALLArinobu Tojo, Kensuke Usuki, Akio Urabe, et al.Pageof 24